Dermata Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)

9 Months Ended

Sep. 30, 2021

Equity Incentive Plan

Schedule of stock option activity

		Number of Options Outstanding				Weighted-Average Exercise Price				Weighted-Average Remaining Contractual Term (in Years)
Balance at December 31, 2020			-			$	-				-
Options granted			523,199				5.84				9.0
Options exercised			-				-				-
Options cancelled			-				-				-
Balance at September 30, 2021			523,199			$	5.84				9.0

Options exercisable at September 30, 2021			233,686			$	5.80				9.3

Weighted-average assumptions used for the stock option grants

		Three Months Ended September 30, 2021				Nine Months Ended September 30, 2021
Grant date fair value		$	4.54			$	4.87
Risk-free interest rate			0.98	%			0.92	%
Dividend yield			0.00	%			0.00	%
Expected life in years			5.8				5.7
Expected volatility			125	%			122	%

Schedule of stock-based compensation expense

		Three Months Ended September 30,								Nine Months Ended September 30,
		2021				2020				2021				2020
Research and development		$	30,075			$	-			$	310,046			$	-
General and administrative			112,580				-				1,106,645				-
		$	142,655			$	-			$	1,416,691			$	-